This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Grading the Twitterverse's 2013 Biotech Stock Picks

BOSTON (TheStreet) -- Last January, I invited my Twitter followers to make their own biotech stock predictions for 2013. Let's check in to see whose crystal ball was in fine working order.

Amarin (AMRN) has been a big loser, which makes @Sport234a2b a big winner!

Nope, but Targacept (TRGT) is up almost 30% this year despite, basically, doing nothing. TRGT ChartTRGT data by YCharts

Cytokinetics (CYTK) closed Friday at $8.18, so you got that right, even after factoring in the 1-for-6 reverse stock split. No ALS data or partner yet and that heart-failure drug isn't looking so hot.

Fail.

Sarepta Therapeutics (SRPT) a volatile stock? You betcha. We're still waiting for the actual eteplrisen filing and expected FDA panel, which are now 2014 events.

Amicus Therapeutics (FOLD) and Incyte (INCY) are still single.

Martin was kidding, I hope.

I hesitate to congratulate Ben for his prescient prediction because it will only swell his already-robust ego.

A.P. Pharma (APPA) is not enjoying 2013: APPA ChartAPPA data by YCharts

But yes, the "A" drug launches pretty much suck, so good on 'ya!

MannKind (MNKD) the stock of the year? Not a chance, but shares are up 146% so you get half credit.

Excellent. You were spot on.

Too easy.

Nope. Very little hepatitis C deal-making this year, but Achillion Pharma's (ACHN) sovaprevir ('1625) remains unpartnered. Correct.

Let's take a look at the year-to-date stock performance of the big-cap biotechs: CELG ChartCELG data by YCharts

Celgene (CELG)... Booyah!

Arena Pharma's (ARNA) Belviq launch has been a near disaster. Half credit.

O-fer. Better luck next year.

I don't know what Opko Health (OPK) actually did this year to validate its diagnostics business, but the stock worked. OPK ChartOPK data by YCharts

Congrats. Well done.

Vikram wins best prediction of 2013.

It has been a good year for deal making, maybe not as much as M&A as you predicted however.

The chart says: "Incorrect!" SGMO ChartSGMO data by YCharts

Nice call on Anacor Pharma (ANAC), but it does illustrate some of the absurd stock moves during this year's biotech bubble. ANAC ChartANAC data by YCharts

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs